GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mithra Pharmaceuticals SA (CHIX:MITRAb) » Definitions » Gross Profit

Mithra Pharmaceuticals (CHIX:MITRAB) Gross Profit : €41.71 Mil (TTM As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Mithra Pharmaceuticals Gross Profit?

Mithra Pharmaceuticals's gross profit for the six months ended in Jun. 2023 was €-1.40 Mil. Mithra Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Jun. 2023 was €41.71 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Mithra Pharmaceuticals's gross profit for the six months ended in Jun. 2023 was €-1.40 Mil. Mithra Pharmaceuticals's Revenue for the six months ended in Jun. 2023 was €7.04 Mil. Therefore, Mithra Pharmaceuticals's Gross Margin % for the quarter that ended in Jun. 2023 was -19.83%.

Mithra Pharmaceuticals had a gross margin of -19.83% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage

During the past 11 years, the highest Gross Margin % of Mithra Pharmaceuticals was 97.42%. The lowest was 30.63%. And the median was 60.77%.

Warning Sign:

Mithra Pharmaceuticals SA gross margin has been in long-term decline. The average rate of decline per year is -13.9%.


Mithra Pharmaceuticals Gross Profit Historical Data

The historical data trend for Mithra Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mithra Pharmaceuticals Gross Profit Chart

Mithra Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 56.31 94.03 5.57 6.94 47.37

Mithra Pharmaceuticals Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.90 3.05 4.27 43.10 -1.40

Competitive Comparison of Mithra Pharmaceuticals's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Mithra Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mithra Pharmaceuticals's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mithra Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where Mithra Pharmaceuticals's Gross Profit falls into.



Mithra Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Mithra Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=66.997 - 19.623
=47.37

Mithra Pharmaceuticals's Gross Profit for the quarter that ended in Jun. 2023 is calculated as

Gross Profit (Q: Jun. 2023 )=Revenue - Cost of Goods Sold
=7.035 - 8.43
=-1.40

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €41.71 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Mithra Pharmaceuticals's Gross Margin % for the quarter that ended in Jun. 2023 is calculated as

Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=-1.40 / 7.035
=-19.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Mithra Pharmaceuticals  (CHIX:MITRAb) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Mithra Pharmaceuticals had a gross margin of -19.83% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage


Mithra Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of Mithra Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Mithra Pharmaceuticals (CHIX:MITRAB) Business Description

Traded in Other Exchanges
Address
Rue Saint-Georges 5, Liege, BEL, 4000
Mithra Pharmaceuticals SA develops products for women's health with a particular focus on fertility, contraception, and menopause. It operates in three segments: Product Sales, Out-licensing, and Other. The company also develops and markets complex therapeutic solutions and offers partners a complete spectrum of research, development, and specialist manufacturing at its Mithra CDMO. Its geographical segments are Belgium, Europe and Outside Europe.

Mithra Pharmaceuticals (CHIX:MITRAB) Headlines

No Headlines